fda has approved annals heimers treatment. the biogen drug is called aduhelm and it is said to slow down the progression of the disease's symptoms. several of the members of the panelmembers of the fda advisory panel resigned as a result of the approval. 11 advisers studied the clinical trial data and not a single member considered the drug ready for approval, not to mention its cost will be steep if it is not covered. biogen could charge $56,000 for an annual course of treatment. nevertheless, others did testify in favor of the drug including the founder and chairman of us against alzheimer's. in an fda panel discussion he argued, quote, if we wait for the perfect drug or perfect data, we will descend further into the grip of this awful disease. people staring into the abyss of alzheimer's deserve no less. he joins me now. george, good to see you, my friend. i thought of you immediately when this news came out. you have argued that this -- basically, don't let perfect be the enemy of the good, but others have argued this drug may not even be good. explain to me your perspective on it. >> well, patients that have no ambiguity about this. we have been waiting for an

the fda panel discussed the rise in cardiac emergency in young people who got the vaccine.s more than twice than anticipated. one professor said before we start vaccinating children we need to find out the consequences. joe biden doesn't want to wait. he promised universal vaccination and he plans to get it done. here he is last week telling you to shut up and take the shot. >> some people say the vaccines were developed so quickly they can't be that good. the bottom line is: i promise you they are safe. they are extremely effective. >> tucker: i promise you say are safe. if the numbers out of israel turnout to be real and applicable to our population that, clip will live forever as the most destructive thing a sitting president has said. the administration should have known this could be coming. pfizer's own clinical trials showed disturbing effects in young people. pfizer gave the vaccine to a group of children between 12 to 15. the rest got a placebo. the fda approved the vaccine for 12 to 15 years old anyway. now the age may be dropping. the "new york times" is reportin

approval of the drug and now the third member of this fda advisory committee aaron from harvard medical school saying that he was quitting this panels probably the worst drug approval decision in u.s. history and not clear that the fda is possible to integrate the scientific recommendations into the approval decisions two other advisers we have reached out who quit this week had similar sentiments and others one said he is staying on the committee but is upset. >> this is getting more strak that it's rare to overturn this -- in the first place about 20% of the time and usually closer vote. why now? why for this alzheimer's drug? the als community is saying why not for us and perhaps there's precedent for acting this way but this particular decision seems more and more out of the ordinary. >> yeah. you have done a lot of research on this. that's why i love you. this committee dealt with a drug a few years ago, a similar situation the clinical data really not clear but a much closer vote from the committee this one almost unanimously against the alzheimer's drug and millions of patients that could take it and it's $56,000 a year and

lisa: there's really a question, given the dissent you saw on the fda panel come on which way the fdago. has their process changed post-pandemic or in the past couple of years in terms of erri ng on the side of, if that can help somebody, why not? sam: i guess that could be something that has gone on here, but i have to say that i don't think necessarily the process has changed. we have seen examples of this kind of outcome before. the one before this was the situation with -- with the drug for muscular dystrophy. the same kind of eyebrows were raised after that. so i don't want to necessarily call this a paradigm shift in the way the fda does its job. lisa: how much does it shift the burden to insurance companies on whether to approve this kind of medicine given the expense, $56,000 for the medication? is this unusual, for insurance companies have such an incredible say in whether it is appropriate or not? sam: absolutely. in europe we get regulatory bodies who do have that mandate. here in the u.s., the fda approval, the label for the drug is so broad relative to what the data actua

a third person has now quit the fda panel following approval of the drug to treat alzheimer's. eli lilly down 4.5%. bio tech down today and up 5% this week thanks to that boost you can see there up 5.5%. meantime watching supply distrupgss labor shortages and other risks that don't seem to be bruising the market's big ego investors are buying into the idea that growth is strong and inflation is transitory. what if they're wrong? steve liesman is here with more. >> the idea that the surge in inflation is term rare looks to be conventional wisdom in markets and could be right but markets seem to have swung from inflation panic to inflation serenity the 10-year benchmark done nothing but rally since the jobs report on friday and the raging 5% cpi report yesterday extending the rally in which yields fell to 1.459 not everyone is so sure inflation is so temporary. some believe the fed purchases to distort the economy joel naroff said businesses didn't have this pricing power in decades and they will get used to it they pass the prices to consumers. hopes that the process plays its o

that's what an fda panel is discussing. today, the talk was contentious. one panel member is counseling caution. he joins us tonight along with our own dr. sanjay gupta. >>> the other story is a deal on infrastructure and what to make of it. $578 billion in new money over spending and no tax hike to pay for it. it's the product of a bipartisan group of senate negotiators. because of how fragile bipartisan anything can be in washington, there's reason to be skeptical about what happens next. joining us now, cnn chief political correspondent dana bash. i understand you have details on the senators involved. what kind of compromise they reached and how big it is. >> we don't have the actual paper, so to speak, of the details of this bill -- of this deal. the fact that we do have that statement, john, from five democrats and five republicans saying full stop they have a deal -- i know the bar is low in washington, but that is a big deal. why that is a big deal is, because we don't see and hear a lot of bipartisanship these days. but also because what i was tol

. >>> and the third member of the fda panel resigned over the agency's decision to approve alzheimer'se resignation letter obtained by cnbc, dr. keslein called the decision probably the worst drug approval decision in recent u.s. history. we are back afr is mmci bakteth (naj) at fisher investments, our clients know we have their backs. (other money manager) how do your clients know that? (naj) because as a fiduciary, it's our responsibility to always put clients first. (other money manager) so you do it because you have to? (naj) no, we do it because it's the right thing to do. we help clients enjoy a comfortable retirement. (other money manager) sounds like a big responsibility. (naj) one that we don't take lightly. it's why our fees are structured so we do better when our clients do better. fisher investments is clearly different. the wm phoenix open golf tournament is one of the largest spectator events in north america. it's also a zero waste event, which means everything thrown away by the hundreds of thousands of people at the tournament is repurposed. in 2020, wm diverted 988 to

that's what an fda panel is discussing, and today, the talk was contentious. covid but one panel member is counseling caution. he joins us tonight, shortly, along with our own dr. sanjay gupta. the other, breaking story, is a deal on infrastructure and just what to make of it. in a nutshell, $578 billion in new money over present spending and no tax hikes to pay for it. it is the product of a bipartisan group of senate negotiators. how fragile bipartisan anything can be in washington, there is reason to be skeptical about what happens next. so joining us now, cnn chief political correspondent, dana bash. host of cnn's state of the union. dana, you have been working the phones, and i understand you have some brand-new details on the group of senators involved. what kind of compromise they reached and how big it is. >> well, you know, we -- we

that's what an fda panel is discussing. today, the talk was contentious.is counseling caution. he joins us tonight along with our own dr. sanjay gupta. >>> the other story is a deal on infrastructure and what to make of it. $578 billion in new money over spending and no tax hike to pay for it.

that's what an fda panel is discussing, and today, the talk was contentious. at least 314 children have died of covid but one panel member is counseling caution. he joins us tonight, shortly, along with our own dr. sanjay gupta. the other, breaking story, is a deal on infrastructure and just what to make of it. in a nutshell, $578 billion in new money over present spending and no tax hikes to pay for it. it is the product of a bipartisan group of senate negotiators. how fragile bipartisan anything can be in washington, there is reason to be skeptical about what happens next. so joining us now, cnn chief political correspondent, dana bash. host of cnn's state of the union. dana, you have been working the phones, and i understand you have some brand-new details on the group of senators involved. what kind of compromise they reached and how big it is. >> well, you know, we -- we don't have the actual paper, so to speak, of the details of this bill. of this deal. but the fact that we do have that statement, john, from five democrats and five republicans. saying, f

setting to give the drug. >> but it doesn't come without controversy, because the fda's own independent advisory paneloted against -- they did not want to recommend the drug but the fda approved it anyway. what were their concerns and how rare is it for the fda to go against their own panel's advice? >> well, i think first of all the second half of your question is it does happen. that's why these approvals and authorizations are not a foregone conclusion but controversy for two main reasons. number one, efficacy. in clinical trials one did not show any effect and one showed a very, very marginal effect on an 18-point scale. only a fraction of a point of improvement and the second is this theory about how it works. that theory about these beta-amyloid proteins or plaque is a theory. it is not generally accepted. so, again, when you talk about efficacy, that's part of the reason for controversy here. safety, when you talk about 40% risk of brain swelling, 17% of people in clinical trials had microscopic hemorrhages. risk/benefit, it's not clear cut. >> it's not clear cut. all right, doc, thank you so m

just today the fda advisory panel to discuss the rise in cardiac emergencies and young people who receive vaccine. so far the rate of myocarditis is more than twice what i authorities anticipated. as one tufts medical school professor who sits on the panel put it "before we start vaccinating millions of adolescents and children is important to find out what the consequences are. you think it would be important to find out but joe biden doesn't want to wait. biden promised a universal vaccination whether we need it or not any plans to get it done. here he is last week telling you to shut up and take the shot. >> some people's questions about how quickly the vaccines were developed, they said they are developed so quickly they can't be that good. the bottom line is this, i promise you, they are safe. even more importantly, they are extremely effective. the one i promise you, they are safe. they are safe. if the numbers out of israel turn out to be real and applicable to our country in this population, the clip you just saw will live forever as one of the most destructive things a sitting pr

back home, a focus on chirp, as an fda advisory panel decides what should be considered before authorizingids 11 and younger. >> what they are talking about today is the nitty gritty, the lonlistics and practicalities of doing clinical trials in children as young as five or even as young as six months of age. >> this morning, moderna filed for mrnl use authorization of its vaccine for 12 to 17-year-olds. pfizer's eua was expanded for 5 to 15-year-olds late last month b a quarter of that age group has now had at least one shot. >> if everybody else gets vaccinated percentage wise, children will be the most susceptible section of our population to get covid. so we need to protect them, first and foremost. >> reporter: more than half the residents in these eight states are now fully vaccinated. nationwide it's just over 42%. >> we knew it was going to get harder as this effort went on. one thing we've learned over anything else is that this vaccination effort will move at the speed of trust. >> reporter: trust with a dose of incentive. >> mark, you won the million dollars. how are you guys do

this comes as fda advisory panel met to discuss the use of the covid-19 vaccine in even younger children. >> i am pretty sure we are going to need the pediatric component of immunity to create the herd immunity we need. >> this shows a possible link between a second dose of the covid-19 vaccine and heart inflammation. cdc says it was a higher number than expected but the cases mostly seen in males are rare. >>> another cdc concern, missed routine vaccinations. >> this is a big concern in the pediatric community especially as kids go back to school. could we start seeing potentially measles out breaks and that sort of thing? >> last month pfizer became first covid vaccine available for kids 12 to 17. >>> live to sfo where the airport is lit up in rainbow lights in celebration of pride month. international terminal will light up in celebration of pride again from the 21st to the 24th and from the 26th to the 28th. it will turn pink in honor of the pink triangle on june 30. >>> going live to oracle park where tonight for the first time ever, san francisco pride and frame line film festival

fda advisory panel over the decision to approve i/o jen -- to approve biogen's alzheimer's drug, butrobably the worst drug approval decision in recent history." to trials produced different results on whether the drug could slow cognitive declined. at the global economy recovers from the pandemic, ripple effects are being felt by everyone from homebuilders to appliance makers. demand is so frenzied that some have stopped taking orders from customers in recent weeks. steel prices in the u.s. have tripled over the past 12 months. global news 24 hours a day, on air and on bloomberg quicktake, powered by more than 2700 journalists and analysts in more than 120 countries. i'm ritika gupta. this is bloomberg. ♪ ♪ tom: "bloomberg surveillance." good morning worldwide. something of great interest to great britain, this is the first lady, mrs. biden, on the obligatory schoolchildren. they look like francine lacqua -- the able to tory school -- the obligatory school tour. they look like francine lacqua's children at a distance. we will have much more from the g7 meetings. our guy johnson in co

no one sees more data than the fda does, however, the fda convened a panel of experts during the fourthdirectly " do you think this drug should be approved?" they said no. what is the point of the fda having these extra panels, if they ignore what they say? anna: what is so controversial about it? what is -- >> two trials were conducted -- one of them failed, one did not. that is not the way trials are done. you say " if this drug works, we are expected to do -- we expected to do -- you say, " if this drug works, we expect it to do x." if you do not find x you cannot go looking for y and z. anna: how unusual is it that the fda approved it? >> the fda often asks for phase four trials. tens of thousands of people will be getting this drug. i have heard one of the top scientists say even 15% of people benefiting from it is enough. the point is it will be interesting how the company then passes through the payment barriers potentially because there were no limitations upon this, not even saying if you are not lowering amuloid, stop. what about the rest of the world? what are they going to s

fda advisory panel over the approval of biogen's alzheimer's drug. third person to quit over the clearance, which he called probably the worst drug approval decision in recent u.s. history. conflicting results were produced on whether the drug can reduce cognitive decline. global news 24 hours a day, on-air and on quicktake by bloomberg, powered by more than 2700 journalists and analysts in more than 120 countries. i am ritika gupta. this is bloomberg. ♪ ♪ >> scaling back on the data. they are reducing the frequency that they are publishing covid related data. i know everybody feels that we are in the homestretch and beyond. data in front of us to make sure we are on the right path and make sure we don't quit before the game is over. tom: jennifer muzze from johns hopkins -- nuzzo from johns hopkins. long ago, mr. -- understood that you took biochemistry and got through organic chemistry and bu ried it was rutgers 355. i pulled this off the website. it was about scientific writing. that is a chorus at your undergraduate level where you realized somed

back home a focus on children as an fda advisory panel decides what should be considered before authorizinghe vaccine for kids 11 and younger. >> what they are talking about today is the nitty-gritty, the logistics and practicalities of doing clinical trials in children as young as five or seven as young as six months of age. >> reporter: moderna just filed for emergency use authorization of its vaccine for 12 to 17 year olds. pfizer's eua was expanded for 12 to 15 year olds late last month, about a quarter of that age group has now had at least one shot. >> susceptible -- >> reporter: more than half the residents in these eight states are now fully vaccinated. nationwide it's just over 42%. >> we knew it was going to get harder as this effort went on but one thing we have learned more clearly than anything else is that this vaccination effort will moved at the speed of trust. >> reporter: trust with dose of incentive. >> mark, you won the million dollars. how are you guys doing? >> it was pretty surreal, you know, from the moment we looked out and we saw you on our doorstep. >> reporter: i

so the fda's independent panel of vaccine advisers will meet in the coming days to discuss the parametersuthorizing covid-19 vaccines for children 11 and under, both moderna and pfizer are testing their vaccines in children's ages 11 and under right now. so sanchez, what do you hope is learned from that meeting? >> gosh, i still hope that the data speaks for itself, fredricka. i really hope this is safe, this is effective in kids who are 11 and younger. i think a lot of my families that i see in my practice are waiting for this. but we really just want want to get ahead of ourselves. we want to make sure we looked at all of the data, every independent expert who needs to look at this and does and no steps are cut here because some are really reliant on us looking at this carefully to make a recommendation for them. and there's many at this point who are eagerly waiting for this to happen. >> and back to the conversation about short term and long term scenarios, how should parents talk to their kids about the whole idea of vaccinations, whether they're eligible, whether the kids in that ca

it is asking fda to expand emergency use of vaccine for kids 12 to 17 years old t comes as fda advisory panel met to discuss the use of the covid-19 vaccine in even younger children. >> i am pretty sure we are going to need the pediatric component of immunity to create the herd immunity we need. >> data shows a possible link between a second dose of the covid-19 vaccine and heart inflammation. cdc says it was a higher number than expected but cases mostly seen in males are rare. >>> reason to be fire ready. so far this year california experienced a 26% increase in wildfire activity and a 58% increase in acres burned compared to last year. we're still weeks away from the fourth of july but illegal fireworks have been going off all over the place already. our assignment editor spotted this illegal show over the oakland hills a couple hours ago. >>> here is why east bay leaders are cracking down. this demo shows how quickly they can set a roof on fire. supervisors just passed a law holding homeowners responsible for any fireworks set off from their property. >>> in newark police seized these ill

. >> reporter: a focus on children as an fda advisory panel decides what should be considered beforezing the covid vaccine for kids 11 and younger. >> what they are talking about today is the nitty-gritty, the logistics and practicalities of doing clinical trials in children as young as 5 or even as young as 6 months of age. >> reporter: among the committee some disagreement on the urgency for these trials as infection rates drop. >> the burden of disease is so small and the risks are just not clear. >> we don't know what's going to happen. i think that's precisely the vision why we want to have these in our arsenal. >> reporter: moderna just filed for emergency use authorization of its vaccine for 12-17 year olds. pfizer was expanded for 12-15-year-olds late last month. about a quarter of that age group has had at least one shot. >> children are going to be the most susceptible section of our population to get covid, so we need to protect them. >> reporter: more than half the residents in these eight states are now fully vaccinated. nationwide it's just over 42%. >> we knew it was g

the approval comes despite an fda advisory panel concluding that there is not enough evidence to supportatment. drugmaker biogen says the treatment slows cognitive decline in patients earlier today on the floor and disease experts said she believes the drug will help slow the progression of the disease. this drug focuses on one of the characteristics of alzheimer's, which is called amyloid or plaque. you may have heard it referred to that. and this drug is what's called a monoclonal antibody, so it uses antibodies to clear the brain of this amyloid plaque. and by doing that it slows the progression of a whole cascade of events that occur in the brains of people with alzheimer's. the drug treatment would cost about $56,000 a year. that is the list price, not the price paid by patients with insurance, santa clara county's largest water provider, is about to take drastic action in response to the drought. valley water is calling for mandatory reductions in water usage, which may mean big changes for customers this summer. ktvu san ruben has more on what to expect. this is an emergency, acco

fda has made. last year the panel concluded there is not enough evidence to support the drug. e benefits outweigh the risks. >>> now for your morning money report. consumer prices around the rise, up 5% in may over the last year and it is fueling concerns about inflation. experts say consumers are spending more now, and there are supply shortages as a result of the pandemic. the pricing increases are across-the-board. beef prices are up more than 2%, closing up nearly 6%, airfare up more than 24% and, as we know well here in california, gas prices are up a staggering 56%. coming up on gma, why top economists are split on whether this inflation is temporary. >>> a live look of the new york stock exchange right now is trading gets underway this morning. we are up about 74 points.>>> the chinese ride hailing giant dd plans to go public in the u.s. it intends to list on either the new york stock exchange or the nasdaq. dd is reportedly seeking a valuation of more than $100 billion. the company describes itself as the world's largest mobility platform offering ride hailing, taxi and

that's despite an assessment from the fda outside panel of experts that found there is not enough evidence to conclude the drug can help patients. the company that makes the drug, biogen says in one study, the drugs slowed mental decline in patients. this is the only drug the u. s regulators have said, can likely treat the underlying disease. rather than manage symptoms, such as anxiety and insomnia. the fda is requiring biogen to conduct a follow up study to confirm the drugs benefits in the city of richmond. there is an effort under way to save a historic lighthouse as ktvu demagogues reports. it's been without power now sends an underwater cable broke just two months ago, and they shorted out and it fried the cable. this is a piece of the 30 year old underwater cable that broke off the east brother light station in april, killing its main power source. we've been scrambling ever sense to figure out what to do. richmond mayor tom but leads the board of directors of the nonprofit that supports the lighthouse. in the last couple days, he says, an electrician spliced what's left of the brok

fda. in november, an advisory panel recommended against approving it saying there wasn't enough evidence to show it worked. the agency today acknowledging that while the expert community has offered differing perspectives on the drug's data, it feels the benefits outweighed the risks of the therapy. the alzheimer's association encouraged by the decision. >> they will have the opportunity and potential to access something that could change their life. >> patients like ronda chant who participated in clinical studies earn couraged by the availability of a new treatment. >> i would say there is a lot of other people like me that say the same thing, let's just get it's not 100%, i'll take the other percent and see if this could help us. >> reporter: a contentious desession giving hope to the millions of americans living with alzheimer's. >>> a direct message today for vice president kamala harris. don't come into the united states if you plan to enter without proper documentation. the vice president issuing that warning during a news conference in guatemala. that was following her meeting with

with this comes as the fda vaccine advisory panel expressed hesitation last week about the emergencya with these studies with kids, talking about the issues we talked about with heart inflammation or the lack of data we have right now. i spoke with the pediatric cardioloist here who tried to settle some of the hesitation around myocarditis. >> myocarditis in kids not vaccinated in the again population, it peaks around the teenage years anyway. i would expect those kids to be more susceptible to begin with. i think some of the cases are kids who would have gotten myocarditis anyway. >> reporter: the parents i spoke to expressed hesitation about this. but these cases of heart inflammation are so rare and way less severe than compared to actually getting covid for their kids. he said it was a no brainer getting kids vaccinated. the 5-year-old wants others to know it didn't hurt that much. he is excited to know that he is exvaccinat vaccinated and others won't get sick. >> that's a great message. doesn't hurt that much. the looks on kids' faces never change. either hiding in their parent

panel. former fda commissioner scott gottlieb who had been a big voice throughout covid whether you agree or disagree with him, talking about the delta variant of the fact that the u.k. is having a surge and he expect we are a month or two behind them and that's not what people want to hear. this hesitancy about vaccinations because some people say it's emergency use authorization only, what is taking the fda so long. do they have the reason they aren't making a definitive decision on the vaccine? >> first of all, in the u.k. it's important to note that we are not seeing a real increase in hospitalizations. the delta strain is more contagious and it's circulating among younger people, if you're vaccinated you don't need to worry about the delta strain and on the second point about, remind me again what you are asking. >> shannon: the fda, it's a mirth -- emergency use. >> a lot of times they are gauging public perception. normally that process is six months to a year. i think we're going to see a decision that's going to be somehow in line with the political bandwagon that's moving from bein

fda has approval monday was controversial. potential side effects include brain inflammation and bleeding. there are mixed results from the clinical trials and an independent panel of experts recommended against fda approval. it certainly is unusual to have a. fda approval. um with one negative andtive trs very exciting, and, uh, but we'll have to wait. it's the only way you can be realistic, right. the doctor says it will likely take a few months for the drug to be given to patients as a treatment. biogen the maker of the drug says it would charge $56,000 a year per patient without insurance in san francisco, amber. lee ktvu, fox two news lawmakers are focusing on a classified report from the lawrence livermore national lab as they look into the origins of the coronavirus. cnn says the paper was drafted in may of last year, it reportedly finds that it is possible that the virus escaped from the lab in wuhan, china, but it also says it could have developed in the wild and gone from animals to humans. secretary of state antony blinken said the white house is looking at both scenarios. so it's i can't put a percentage on it. i think there are two possible um and l

on cognition and function which is the whole point to begin with an independent panel that strongly recommended to the fdat would not approve this drug and fda approved anyhow and members resigned and one said the worst decision he could recall for an fda approval, where that leads us the drug is going to cost $56000 a year 6 million people with all timers in the u.s., the fda wants biogenic to produce more evidence that it makes patients better off but it could have years of sales between now and then and ubs thinks sales will peak at $30 billion a year that's as much money as biogenic made last year the report on thursday tells you what wall street is thinking, like it or not it is going to get used. jack: we are tight on time we have to go but one interesting thing whether insurance companies are willing to pay the $56000. $56000. >> i've seen them push back on much less controversial cases. jack: coming up noisy leaf blowers and lawnmowers from working from home, the ceo stanley black & decker says electric garden tools is good for you and your spending in his business. business. that is ♪ ♪ ♪ busines

fda is approval monday was controversial. potential side effects include brain inflammation and bleeding. there are mixed results from the clinical trials and an independent panel of experts recommended against fda approval. it certainly is unusual to have fda approval, um with with one negative and one positive trial, inspired at the institute of aging monday. mark the first day of in person programs resuming since the pandemic shut down the program director for dementia services says so far families of alzheimer patients have expressed optimism they have sort of said, where do i sign up? how soon can i get this? it's very exciting. and, uh, but we'll have to wait. it's the only way you can be realistic, right? the doctor says it will likely take a few months for the drug to be given to patients as a treatment. biogen the maker of the drug says it would charge $56,000 a year per patient without insurance. alex a lot of controversy surrounding this drug, but obviously a lot of people see hope here, amber thank you. flames broke out at a duplex in the sunnyside neighborhood of san francisco today. the fire was reported around for this afternoon on monterey boule

the fda approval came against the advice of their panel.st, arguing there's insufficient evidence and conflicting evident regarding the benefits and a risk of side effects and then the estimated cost. get this, $56,000 a year, which can single-handedly cost the government billions, even trillions of dollars and seniors and their families thousands of dollars a year. bengy is a policy editor, and he wrote how it could bro up the federal budget, and he joins me now. this is such a fascinating story, and there's a sort of two perfect storm components. one is the cost. let's talk a little bit about what the cost is, why it's so high, and who would pay for it. >> so chris, the cost is put by the company biogen, at $56,000 per year, per patient. and it would be going -- you would go into the doctor's office or a clinic. you would get it as a kind of intravenous treatment, and the cost would be borne probably mostly by medicare because the overwhelming number of alzheimer's patients are seniors who get their care through medicare. some potentially

fda's own advisory. pat, some people on the panel even quit because of this. the drug could cause some patience.2,000 a year, even though the drugmaker biogen says it has priced the drug treatment responsibly. >> plans to get cruz is up and running this summer. the partly they've hit a snag ready to sail. now. no royal caribbean international has announced that the inaugural sailing events. >> new ship has been postponed because crew members have tested positive for covid-19. >> yeah. the introductory cruz has now been pushed back from july. 3rd to july 31st at the earliest. a reporter, brian entin explains the plans going forward. >> the inaugural cruise on royal caribbean's newest ship odyssey of the seas. now delayed after 8 vaccinated crew members tested positive for covid-19 royal caribbean is president and ceo michael bayley making the announcement on his facebook page. 2 steps forward and one step back out of an abundance of caution. we are postponing odyssey's inaugural sailing from july 3rd to july 31st, 2021 royal caribbean says 6 of the crew members are asymptomatic and 2 are experien

wouldn't go through because of course the panel put together to actually recommend or not said no for the approval and this is such an interesting process the fdadespite the panel saying no. >> and by the way a lot of the wall street firms were caught recommending sell because of exactly what you said. you may in the future get a couple extra years but i think there is push back that price is -- >> there is the openin"opening " jim you know a lot about migraine -- >> i know it is going rain later today. i have -- i know it is going rain it is going start around 1:00. when i see it about to rain, i know i'm going to have a very serious high grain even though i takemigraine even though i take -- but this preventative i popped one this morning because i know in five hours hi head is going to be hit by rebar, by a giant -- >> -- glaktically. >> the government just approved it for that. i have a very biometric pressure migraine, where if i hear a noise like my wife loading the dishwasher why are you doing this or the dog or i love dogs but i have wanted to strangle a dog. the sound is greatly amplified. >> -- every day given all those -- >> no but i

. >>> the fda will be adding a warning to two of the covid vaccines. it comes after ac/dc advisory panel found there is a likely association between the vaccines and a rare heart inflammation and young people. >> reporter: the heart condition is called myocarditis and an inflammation of the heart muscle the most common cause is a viral infection. >> your heart muscle is not able to pump as efficiently as it does if it doesn't have a viral inflammation. >> reporter: now word that the m nra bar vaccine may be associated with over 100 cases and young people. the problem is more likely after the second shot. but it is still rare. roughly 12 cases per million doses of the vaccine. >> the bottom line for parents, and i have three children myself who have all been vaccinated is we would still elect to get the vaccine. >> reporter: this doctor is on the cdc panel and the panel said the benefits of vaccine far outweigh any risk. in adolescence and young adults who developed the heart inflammation, the cases were mild. >> many organizations are still recommending vaccinations for anybody 12 or old

. >>> controversy rages after the fda approves an alzheimer's drug against the advice of an ad advisory panelrst on "cbs this morning" we hear from a doctor who resigned from the committeen

fda for approving it. david: that's it for this week's show. thanks to my panel and all of you for watching paul is back next week. we hope to see you then. ♪♪ >> president biden meeting with leaders on the world's largest economies in england urging them to unite in competition against china in rebuilding the world after the pandemic. another set for next week may overshadow the g7 as president biden prepares for a face-to-face meeting with his russian counterparts, vladimir putin. hello, welcome to a brand-new hour of fox news live. i am arthel neville. >> thank you for joining us on this saturday. i am eric shawn. day two of the g7 summit in england, is winding down or not, one of the three big stories we are following at this hour. there's also the florida crisis with thousands of migrants contained over the past seven days, the biden administration is declared at the border is closed. migrants don't come, they are. plus, two people killed, 20 injured. the violence surged in major cities. arthel: live fox news team coverage, live at our southern border. chris

fda for approving it. david: that's it for this week's show. thanks to my panelching paul is back next week. we hope to see you then. ♪♪ >> president biden meeting with leaders on the world's largest economies in england urging them to unite in competition against china in rebuilding the world after the pandemic. another set for next week may overshadow the g7 as president biden prepares for a face-to-face meeting with his russian counterparts, vladimir putin. hello, welcome to a brand-new hour of fox news live. i am arthel neville. >> thank you for joining us on this saturday. i am eric shawn. datw

. >> the fda deciding to approved the drug is controversial. it came after an independent paneloric. we're tracking some of the triple-digit numbers deal tails in the forecast ahead. >>> california's drought drying up lakes and revealing a mystery ject it could be the answer to a 56-year-old question strip away what you don't want, like added sugars and preservatives, and what's left is the good stuff. the real fruit and vegetable juices of naked. strip down to naked. one, two! one, two, three! only pay for what you need! with customized car insurance from liberty mutual! the real fruit and vegetable juices of naked. nothing rhymes with liberty mutual. only pay for what you need. ♪ liberty. liberty. liberty. liberty. ♪ >>> man, the heat wave in the west shattering hundreds of records. by more than ten degrees in some areas, and the forecasters saying it's about to get even hotter in death valley questioned, the therm other meter hit 124. today, 128, nearing the highest temperature every recorded on planet earth, 134 in death valley as far north as billings, montana, people felt

the company today asked the fda to expand emergency use of its vaccine for kids 12 to 17 years old. it comes as an at the advisory panel met to discuss the use of the covid-19 vaccine in young children. >> i'm pretty sure we are going to need the pediatric component of immunity to create the herd immunity we need. >> last month pfizer became the first vaccine available for that age group. >>> not our captain of the states reopening on tuesday. we are just a little more than four days away. and there is anger and confusion over the mixed messages about masks, as most covid related restrictions come to an end on tuesday. reporter alex piston explains why we may not know what we are supposed to do until after the june 15th reopening. >> reporter: mask up or toss them out? business owners and employees are confused as the state is gearing up to ease pandemic restrictions on june 15th. >> it has been confusing for a very long time. >> i just keep my mask on just to be safe. >> reporter: they are the agency in charge of workplace regulations for the state. in a meeting last night a rescinded an order saying employees can sto

may be don't have to go think about the last stage >> the fda approval to approve this drug is controversial it came after an independent panelrts said the data did not convince them at all >>> the heat in the west is incredible and in some places, historic we're tracking some of the triple digit numbers details and the forecast ahead >>> california's drought, drying up lakes, and in one case, revealing a mystery object now some believe it could be the answer to a 56-year-old question so it's another day. yeah- that's what most people think. but in business it's never just another day. every day is the day. there's the day your store has its biggest sale. the day you have a make or break presentation. and the day your team operates from across the country. but there's also the day you never see coming- the day when nothing goes right. see- that's the thing. you never know what the day might bring. so whether you do business on wall street or main street you have to be ready. with the power of the network that can deliver gig speeds to the most businesses. the freedom to control that network from anywhere. and advanced cyberse

may be don't have to go think about the last stage >> the fda approval to approve this drug is controversial it came after an independent panel them at all >>> the heat in the west is incredible and in some places, historic we're tracking some of the triple digit numbers details and the forecast ahead >>> california's drought, drying up lakes, and in one case, revealing a mystery object now some believe it could be the answer to a 56-year-old question crash-tested so many cars we've stopped counting. and built our most punishing test facility yet, in our effort to build the world's safest cars. we've created crumple zones and autonomous braking. active lane keeping assist and blind spot assist. we've introduced airbags, side curtain airbags, and now the first-ever rear-mounted front-impact airbags. all in the hope that you never need any of it. >>> man, the heat wave in th >>> man, the heat wave in the west shatteringhundreds of records. by more than ten degrees in some areas. the forecasters say it is about to get even hotter in death valley yesterday, the thermometer hit 124. today, 128 nearing the highest at that ever reco

but tonight, word from the fda, they're extending the shelf life of the johnson & johnson vaccine by six weeks. here's marcus moore. >> reporter: an expert panel today taking a closer look at reports of heart inflammation among young people after they receive the pfizer and moderna vaccines. the cdc now reporting preliminary data of 226 cases of myocarditis in people younger than 30 out of millions of people vaccinated. so far, there is no firm link to the vaccine. though still rare, the case numbers are higher than the cdc would expect to see in the general population. >> when you see myocarditis, it tends to be found within a few days, two to three days after the second dose of the vaccine. and it seems to start with chest pain, shortness of breath and exercise intolerance. >> reporter: doctors are being told to look out for symptoms just like that, but cases appear to be mild and go away with treatment. moderna today joining pfizer in applying for authorization for its vaccine for 12 to 17-year-olds. just 28% of that age group has gotten their first dose. some parents are still not ready to vaccinate their children. >> i would prefer to wai

a cdc panel tonight revealing they have now concluded that there is a, quote, likely association between the vaccine and the inflammation. the fda now finalizing a new warning that will go out to health care providers, parents and the public, but the cdc and all of its advisers tonight still say the benefits of being vaccinated far outweigh the r risks, sayi iing the risk of he inflammation is more likely with covid than the vaccine. there is concern not enough young people have been vaccinated. just a third of people 18 to 24 have now been vaccinated. tonight, the numbers here. 177 million americans have had at least one dose. that's about 62% of people 12 years and older. and this evening, that moment with the first lady, dr. jill biden on stage, an event with brad paisley, part of a push to get more people vaccinated. and how the crowd reacted to the numbers. and news tonight from a cdc working group just on whether americans will need boosters. here's abc's eva pilgrim tonight. >> reporter: tonight, a cdc panel finding a likely association between the pfizer and moderna vaccines and a rare, mostly mild, heart inflammation in